Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 556-561

  Chow, Sheryl L ^a,c   Peng, Jessica T ^a   Okamoto, Mark P ^a   Heywood, J Thomas ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b SCRIPPS CLINIC   (United States)

^c Scois Speakers Bureau   (United States)

Author keywords

Heart failure; Nesiritide; Renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CHLOROTHIAZIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; INOTROPIC AGENT; METOLAZONE; NESIRITIDE; NITROGEN; SPIRONOLACTONE; UREA;

ACUTE HEART FAILURE; ADULT; AGED; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INFUSION RATE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; UREMIA;

AGED; BLOOD UREA NITROGEN; CREATININE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LOGISTIC MODELS; MALE; MEDICAL RECORDS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; RETROSPECTIVE STUDIES;

EID: 34247273504     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H589     Document Type: Review

References (21)

1. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.
2. Colucci W, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
3. Jensen KT, Hans E, Carstens J, et al. Renal effects of brain natriuretic peptide patients with congestive heart failure. Clinic Sci 1999;96:5-15.
4. Lainchbury JG, Richards AM, Nichollis MG, et al. Infusion or co-infusion of brain natriuretic peptide and/or adrenomedullin in human heart failure (abstract). J Am Coll Cardiol 1998;31:156A.
5. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
6. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
7. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the Precedent study. Am Heart J 2002;144:1102-8.
8. Adams KF, Marco TD, Berkowitz R, et al. Inotrope use and negative outcomes in treatment of acute heart failure in patients with preserved systolic function: data from the ADHERE database (abstract). Circulation 2003;108:695.
9. Sackner-Bernstein JD, Skopicki HA, Aaronson K. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
10. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure classification and regression tree analysis. JAMA 2005;293:572-80.
11. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8.
12. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function congestive heart failure. J Card Fail 2002;8:136-41.
13. Krumholz H, Chen Y, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients >65 years of age with heart failure. Am J Cardiol 2000;85:1110-3.
14. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13-25.
15. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose (abstract). Circulation 2005;112:589.
16. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine (abstract). Circulation 2005; 112:451-2.
17. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am J Cardiol 2004;94:595-601.
18. Bakris GL, Weir MR. Angiotensin-Converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
19. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004;110:1620-5.
20. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA 2002;287:1531-40.
21. Iglesias J, Lieberthal W. Clinical evaluation of acute renal failure. In: Johnson RJ, Fehally J, eds. Comprehensive clinical nephrology. London: Mosby, 2000:4.15.1-4.15.15.